Piramal Pharma Reports Q2 Profit Of Rs5.03 Crore

Consolidated revenue stood at Rs2,617.06 crore, up from Rs2,043.72 crore in the previous year.

Reader Takeaway: Revenue growth and Yapan Bio consolidation improve financials, though standalone profit margins show slight pressure.

What just happened

Piramal Pharma (PPL) announced its unaudited financial results for the quarter ended September 30, 2026. The company successfully swung to a consolidated profit of Rs5.03 crore from a loss of Rs99.22 crore a year ago. Simultaneously, the company finalized the acquisition of an additional 40.67% stake in Hyderabad-based Yapan Bio, bringing its total ownership to 74%. The deal was completed for Rs76.09 crore, officially classifying Yapan Bio as a subsidiary.

Why this matters

The transition of Yapan Bio into a subsidiary is a strategic move to strengthen PPL's position in the biologics and vaccines CDMO space. For investors, the consolidation of Yapan Bio's financials into the group's results will be critical to monitor for future growth. The revenue jump on a consolidated basis indicates better operational performance compared to the prior year, even as the standalone entity saw profit dip slightly to Rs170.74 crore from Rs196.33 crore.

Risks to watch

As PPL integrates Yapan Bio, the company is currently using the 'measurement period' exemption under IND AS 103 for provisional goodwill and asset valuations. Final fair valuations and purchase price allocations are expected by the end of the year, which could lead to accounting adjustments in upcoming filings.

Context metrics

Consolidated revenue for the quarter reached Rs2,617.06 crore. Earnings per share (EPS) turned positive at 0.04 compared to a negative 0.75 in the same period last year. Yapan Bio now operates under the PPL group umbrella as a 74% owned subsidiary.